Net Cash Provided by (Used in) Financing Activities in USD of Theravance Biopharma, Inc. from 2015 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Theravance Biopharma, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2015 to Q1 2025.
  • Theravance Biopharma, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was -$854K, a 50.2% increase year-over-year.
  • Theravance Biopharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was -$2.5M, a 98.7% increase from 2023.
  • Theravance Biopharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was -$199M, a 73.8% increase from 2022.
  • Theravance Biopharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$759M, a 926% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Theravance Biopharma, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$854K +$862K +50.2% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-12
Q1 2024 -$1.72M +$54.5M +96.9% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-12
Q1 2023 -$56.2M -$54.8M -3784% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q1 2022 -$1.45M +$9.84M +87.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q1 2021 -$11.3M -$273M -104% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q1 2020 $261M +$263M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q1 2019 -$1.43M +$247K +14.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q1 2018 -$1.68M -$464K -38.2% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q1 2017 -$1.22M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09

Theravance Biopharma, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$2.5M +$196M +98.7% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-07
2023 -$199M +$560M +73.8% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-07
2022 -$759M -$851M -926% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-01
2021 $91.9M -$171M -65.1% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-01
2020 $263M +$262M +20278% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-01
2019 $1.29M -$224M -99.4% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $225M +$224M +13499% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 $1.66M -$478M -99.7% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
2016 $479M +$398M +489% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 $81.3M Jan 1, 2015 Dec 31, 2015 10-K 2018-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.